Vantage Financial Partners Ltd., Inc. Biogen Inc. Transaction History

Vantage Financial Partners Ltd., Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 12, 2020	SELL	$268.85 - $341.04 $524,257 - $665,028	-1,950 Closed	0 $0
Q4 2019 Jan 27, 2020	BUY	$220.06 - $304.07 $11,003 - $15,203	50 Added 2.63%	1,950 $579,000
Q3 2018 Nov 02, 2018	SELL	$293.51 - $383.83 $58,702 - $76,766	-200 Reduced 9.52%	1,900 $671,000
Q1 2018 May 07, 2018	BUY	$260.13 - $367.91 $26,013 - $36,791	100 Added 5.0%	2,100 $575,000
Q4 2017 Feb 09, 2018	SELL	$307.64 - $344.58 $93,522 - $104,752	-304 Reduced 13.19%	2,000 $638,000
Q3 2017 Nov 02, 2017	BUY	$281.15 - $329.69 $113,584 - $133,194	404 Added 21.26%	2,304 $645,000
Q2 2017 Aug 14, 2017	BUY	N/A	1,385 Added 268.93%	1,900 $515,000
Q2 2017 Aug 10, 2017	BUY	N/A	515	515 $515,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Vantage Financial Partners Ltd., Inc., based on Form 13F filings with the SEC.

Stay updated on Vantage Financial Partners Ltd., Inc. with notifications on news.